Exelixis, Takeda and Japanese RCC Patients
Today we learned from Exelixis (EXEL) that Takeda Pharmaceutical Company Limited, which is responsible for the clinical development and commercialization of Exelixis' oncology drug CABOMETYX® (cabozantinib . . .
This content is for paid subscribers.
Today’s Highlights
March 25, 2020
